Ushering in the study and treatment of preclinical Alzheimer disease

Jessica B. Langbaum, Adam S. Fleisher, Kewei Chen, Napatkamon Ayutyanont, Francisco Lopera, Yakeel T. Quiroz, Richard J. Caselli, Pierre N. Tariot, Eric M. Reiman

Research output: Contribution to journalReview articlepeer-review

97 Scopus citations


Researchers have begun to characterize the subtle biological and cognitive processes that precede the clinical onset of Alzheimer disease (AD), and to set the stage for accelerated evaluation of experimental treatments to delay the onset, reduce the risk of, or completely prevent clinical decline. In this Review, we provide an overview of the experimental strategies, and brain imaging and cerebrospinal fluid biomarker measures that are used in early detection and tracking of AD, highlighting at-risk individuals who could be suitable for preclinical monitoring. We discuss how advances in the field have contributed to reconceptualization of AD as a sequence of biological changes that occur during progression from preclinical AD, to mild cognitive impairment and finally dementia, and we review recently proposed research criteria for preclinical AD. Advances in the study of preclinical AD have driven the recognition that efficacy of at least some AD therapies may depend on initiation of treatment before clinical manifestation of disease, leading to a new era of AD prevention research.

Original languageEnglish (US)
Pages (from-to)371-381
Number of pages11
JournalNature Reviews Neurology
Issue number7
StatePublished - Jul 2013

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Ushering in the study and treatment of preclinical Alzheimer disease'. Together they form a unique fingerprint.

Cite this